1. Conduct prospective clinical studies to evaluate the efficacy and safety of different GLP-1 receptor agonists in patients with DM1.2. Perform pharmacogenetic studies to explore the relationship between GLP-1R gene variations and drug efficacy.3. Investigate the direct effects on muscle pathology by studying whether GLP-1 receptor agonists can improve muscle inflammation, fibrosis, and other pathological changes.4. Design studies targeting specific subgroups to assess the potential value of GLP-1 receptor agonists in DM1 patients with concomitant metabolic syndrome. This evidence concerns the gene GLP1R and myotonic dystrophy type 1.